Depo-Eligard

PreclinicalSmall molecule

Astellas

Depo-Eligard is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Phase 3

14 2

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 3

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 4

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

2 5

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 8

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Recruiting

Prostate Cancer

NCT06282588

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Completed· Astellas logo

Astellas··NCT01793077·259 enrolled

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting·CCancer Research Antwerp·Phase 2/3·NCT06282588·493 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Depo-Eligard. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Depo-Eligard compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Depo-Eligard. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Astellas

Depo-Eligard

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Prostate Cancer2 trials

References

Drug Info

Quick Facts

Related News